Dergiler / The anatolian journal of family medicine (Online) / 2020 / Cilt: 3 - Sayı: 2

Evaluation of HBV and HCV Seroprevalence in Serum Samples of Individuals Diagnosed with Hepatocellular Carcinoma

Sayfa
116–120
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

HBV still keeps its importance in the etiology of HCC.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Objectives: According to the data of the World Health Organization, hepatocellular carcinoma (HCC) is the fifthmost common cancer and the second leading cause of cancer-related deaths.
📊
Temel Bulgular & Veri:The patients with HCC who wereanalyzed HBsAg and anti-HCV antibody in serum specimens in Virology Laboratory between October 2016 andDecember 2018.
💡
Sonuç & Katkı:HBV still keeps its importance in the etiology of HCC.
🔬Tür:Araştırma Makalesi
📍Kapsam:2016 Verileri
⚙️Değişkenler:Alan Parametreleri

Özet

Objectives: According to the data of the World Health Organization, hepatocellular carcinoma (HCC) is the fifthmost common cancer and the second leading cause of cancer-related deaths. This study aimed to investigate theimportance of hepatitis B virus (HBV) and hepatitis C virus (HCV) in the viral etiology of HCC. In this study, we evaluated HBsAg and anti-HCV test results in serum samples sent with the diagnosis of HCC to Virology Laboratory.Methods: This study was planned as a record-based cross-sectional study. The patients with HCC who wereanalyzed HBsAg and anti-HCV antibody in serum specimens in Virology Laboratory between October 2016 andDecember 2018. HBsAg and anti-HCV were tested in serum samples with test parameters chemiluminescentmicro-particular enzyme immunoassay method by Architect system.Results: This study included 44 patients with HCC. The median age of the patients diagnosed with HCC was 64.0(33.0-88.0) years. Thirty-six (81.8%) of the patients were male, and 8 (18.2%) were female. HBsAg seropositivitywas found in 13 (29.5%) patients and anti-HCV seropositivity was found in 2 (4.6%). HBsAg seropositivity wasfound in 2 (25.0%) of female patients and 11 (30.6%) of male patients (p=0.755). Anti-HCV seropositivity wasfound in 2 (5.6%) male patients (p=0.666). The highest HBsAg rate was 35.3% in the age group of 50-69 years, andthe highest anti-HCV rate was 14.3% in the age group of 70-88 years (p=0.415, p=0.407, respectively).Conclusion: As a result, HBsAg seropositivity was found in 29.5%, and anti-HCV seropositivity was found in4.6% of the patients diagnosed with HCC. HBV still keeps its importance in the etiology of HCC.

🔖

Bu Makaleye Atıf Yap

BAKIR, A., ALBAYRAK, H., GÜNEY, M., YAVUZ, M. (2020). Evaluation of HBV and HCV Seroprevalence in Serum Samples of Individuals Diagnosed with Hepatocellular Carcinoma. The anatolian journal of family medicine (Online), Cilt: 3 - Sayı: 2, 116–120. https://ajindex.com/articles/365013

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (14)

  1. Balogh J, Victor D 3rd, Asham EH, Burroughs SG, Boktour M, Saharia A, et al. Hepatocellular carcinoma: a review. J Hepatocell Carcinoma 2016;3:41–53
  2. Chang IC, Huang SF, Chen PJ, Chen CL, Chen CL, Wu CC, et al. The Hepatitis Viral Status in Patients With Hepatocellular Carcinoma: a Study of 3843 Patients From Taiwan Liver Cancer Network. Medicine (Baltimore) 2016;95:e3284
  3. El-Serag HB. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology 2012;142:1264–73.e1
  4. Chen CJ, Yu MW, Liaw YF. Epidemiological characteristics and risk factors of hepatocellular carcinoma. J Gastroenterol Hepatol 1997;12:S294–S308
  5. Global Burden of Disease Liver Cancer Collaboration, Akinyemiju T, Abera S, Ahmed M, Alam N, Alemayohu MA, et al. The Burden of Primary Liver Cancer and Underlying Etiologies From 1990 to 2015 at the Global, Regional, and National Level: Results From the Global Burden of Disease Study 2015. JAMA Oncol 2017;3:1683–91
  6. Rawla P, Sunkara T, Muralidharan P, Raj JP. Update in global trends and aetiology of hepatocellular carcinoma. Contemp Oncol (Pozn) 2018;22:141–50
  7. Sangiovanni A, Prati GM, Fasani P, Ronchi G, Romeo R, Manini M, et al. The natural history of compensated cirrhosis due to hepatitis C virus: A 17-year cohort study of 214 patients. Hepatology 2006;43:1303–10
  8. Ioannou GN, Splan MF, Weiss NS, McDonald GB, Beretta L, Lee SP. Incidence and predictors of hepatocellular carcinoma in patients with cirrhosis. Clin Gastroenterol Hepatol 2007;5:938–45.e9454
  9. Lok AS, Seeff LB, Morgan TR, di Bisceglie AM, Sterling RK, Curto TM, et al. Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease. Gastroenterology 2009;136:138–48
  10. Chitapanarux T, Phornphutkul K. Risk Factors for the Development of Hepatocellular Carcinoma in Thailand. J Clin Transl Hepatol 2015;3:182–8
  11. Murakami T, Baron RL, Peterson MS, Oliver JH 3rd, Davis PL, Confer SR, et al. Hepatocellular carcinoma: MR imaging with mangafodipir trisodium (Mn-DPDP). Radiology 1996;200:69– 77
  12. Liu CJ, Kao JH. Hepatitis B virus-related hepatocellular carcinoma: epidemiology and pathogenic role of viral factors. J Chin Med Assoc 2007;70:141–5
  13. Verme G, Brunetto MR, Oliveri F, Baldi M, Forzani B, Piantino P, et al. Role of hepatitis delta virus infection in hepatocellular carcinoma. Dig Dis Sci 1991;36:1134–6
  14. Suruki RY, Mueller N, Hayashi K, Harn D, DeGruttola V, Raker CA, et al. Host immun